FibroGen droht Delisting from the Nasdaq Aktienkurs Von Investing.com

SAN FRANCISCO, CA – FibroGen, Inc., a pharmaceutical company that has begun reporting stocks on the Nasdaq stock market, has a 30-month trading date with a $1.00 lag.

The Benachrichtigung took place on September 12, 2024, which means that the Börsennotierung has not ended.

The date of the update NASDAQ:FGEN was announced on March 11, 2025. This is the time when Compliance will be updated. Während dieser 180-tags First muss FibroGen und mindestens zehn aufeinanderfollowgenden Handelstagen een Schlusskurs von mindestens 1.00 US-Dollar pro Aktie erreichen. For best results, some of the first 180 days can be used.

FibroGen is the best that all other Nasdaq erstnotierungsstandaard inherited, with the best bone spreads. The company factory, the bone spread blessing, is active in the überwachen and options for the operation of the mangles in the prüfen. It may be that there is an agreement between the companies that made the Nasdaq purchase.

The information required is based on an 8K submission.

In other active roles, FibroGen Inc. in the Rahmen market, charge cost-saving costs in the Führungsteam. Finanzvorstand Juan Graham and Chief Medical Officer Deyaa Adib were able to work together for this month. Planted since November. This writer is one of the following strategies for the strategy of the onternehmensabläufe.

In the last years of the Entwicklungen-verzeichnete FibroGen in the quarter 2024 both Rückschläge and auch Fortschritte. The internal message of a erheblichen Enttäuschung beim Scheitern von Pamrevlumab in Bauchspeicheldrüsenkrebs-Studien, was an umfangreichen cost plan that had become a 75% long reduction of the US-Belegschaft. Trotzdem notified fibrogen that it was possible to use drugs with the FG-3246 for metastatic castration-resistant prostatakrebs und anhaltenende erolge with roxadustat in China.

The future of the future was a strong forecast for net production and the Roxadustat net allocation in China for the year 2024, was a strong financial position and a potential for strategic partnerships. The total allocation for the second quarter of 2024 continued to grow 14% in the years, mainly due to the Roxadustat sales in China, which received a value of 21%. Despite a net surplus of US$15.5 million for Q2 2024 FibroGen has an active cash position in the financing of 2026 to finance.

InvestingPro Introduction

When FibroGen is confronted with the Herausforderungen of the Nasdaq-Mindestgebotspreisrule-, says a genauerer Blick on the financial financing and market analysis of the Unternehmens and hand of InvestingPro-Daten and -Tips a different Bild. FibroGen’s market capitalization was a modest US$46.18 million and was more broadly reflected by investors. Trotz eines beachtlichen Umsatzwachstums of 33.11% in the last two months of Q2 2024 were able to cope with the external losses with gross profit margins of -34.4%, was due to operative changes in hindrance. The action with a strong performance of 28.59% in a volatile price, but a steep price increase of 77.51% in the last six months’ period, was a new challenge.

InvestingPro-Tipps said that the fibro generation had high trading activity, with a large amount of money, the odds of a strange company were that the bet would yield another financial financing. It is not that analysts do not know the benefits of a profitable world, and the Bewertung implies a poor Free Cash Flow Yield. These factors must be weighed by investors if the Company’s strategy for Nasdaq compliance is used and longevity in the fight is seen.

For those years, which are one of the best analyses, there are 10 other InvestingPro Tips available, which can mean a few things, a foundation fund investor about the results of FibroGen that they have removed. These tips will give you real insights on the dedicated InvestingPro page for fibrogen at https://de.investing.com/pro/FGEN.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.